Idioma:

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Abou-Alfa, Ghassan K ; Meyer, Tim ; Cheng, Ann-Lii ; El-Khoueiry, Anthony B ; Rimassa, Lorenza ; Ryoo, Baek-Yeol ; Cicin, Irfan ; Merle, Philippe ; Chen, YenHsun ; Park, Joong-Won ; Blanc, Jean-Frederic ; Bolondi, Luigi ; Klümpen, Heinz-Josef ; Chan, Stephen L ; Zagonel, Vittorina ; Pressiani, Tiziana ; Ryu, Min-Hee ; Venook, Alan P ; Hessel, Colin ; Borgman-Hagey, Anne E ; Schwab, Gisela ; Kelley, Robin K

The New England journal of medicine, 2018-07, Vol.379 (1), p.54-63 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Autor: Abou-Alfa, Ghassan K ; Meyer, Tim ; Cheng, Ann-Lii ; El-Khoueiry, Anthony B ; Rimassa, Lorenza ; Ryoo, Baek-Yeol ; Cicin, Irfan ; Merle, Philippe ; Chen, YenHsun ; Park, Joong-Won ; Blanc, Jean-Frederic ; Bolondi, Luigi ; Klümpen, Heinz-Josef ; Chan, Stephen L ; Zagonel, Vittorina ; Pressiani, Tiziana ; Ryu, Min-Hee ; Venook, Alan P ; Hessel, Colin ; Borgman-Hagey, Anne E ; Schwab, Gisela ; Kelley, Robin K
Assuntos: Adult ; Aged ; Aged, 80 and over ; Anilides - adverse effects ; Anilides - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Aspartate aminotransferase ; Axl protein ; Cancer ; Cancer therapies ; Carcinoma, Hepatocellular - drug therapy ; Collaboration ; Diarrhea ; Disease-Free Survival ; Double-Blind Method ; Fatigue ; Female ; Growth factor receptors ; Hepatitis ; Hepatocellular carcinoma ; Hospitals ; Humans ; Kaplan-Meier Estimate ; Life Sciences ; Liver cancer ; Liver Neoplasms - drug therapy ; Male ; Medical prognosis ; Middle Aged ; Oncology ; Patients ; Pyridines - adverse effects ; Pyridines - therapeutic use ; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors ; Survival ; Tumors ; Tyrosine ; Vascular endothelial growth factor ; Vascular endothelial growth factor receptors
É parte de: The New England journal of medicine, 2018-07, Vol.379 (1), p.54-63
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Descrição: Among patients with hepatocellular carcinoma whose disease had progressed during receipt of sorafenib or other systemic therapy, median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo. High-grade adverse events were as previously noted for the drug.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.